AI Consensus Investment Thesis
ISRG: Intuitive Surgical Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Intuitive Surgical: 1-Year and 5-Year Forecast Outlook and Rating
Intuitive Surgical (ISRG) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $432 for , with -1.37% expected return (-1.37% including net dividends) and a PARTIAL SELL rating.
The 5-year target is $663 for , with +51.37% expected return (+51.37% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 438, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Intuitive Surgical Flagship Insight
Robotic Surgical Monopoly Confronts Hospital Capital Rationing And Margin Concessions
There is high consensus that non-discretionary surgical procedure volumes and recurring consumable sales insulate cash generation from macroeconomic volatility. However, sharp divergence exists regarding valuation durability, as elevated interest rates, operating-lease mix shifts, and arriving multiport competition threaten long-term profit margins.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Ray Dalio (Strategist)
Machiavelli (Insider)
Universal Investor (Polymath)
Warren Buffett (Value Purist)
Superintelligence (Anthropologist)
Sherlock Holmes (Whistleblower)
Elon Musk (Visionary)
Michael Burry (Vulture)
J.P. Morgan (Titan)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Intuitive Surgical: forecast questions
What is Intuitive Surgical (ISRG)'s 1-year price forecast?
Intuitive Surgical's 1-year target is $432 for Sept 2027. The current AI rating is PARTIAL SELL. The expected return from the recorded close is -1.37%, or -1.37% modeled return including net dividends. Latest available market price: USD 438, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Intuitive Surgical (ISRG)'s 5-year price forecast?
Intuitive Surgical's 5-year target is $663 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +51.37%, or +51.37% modeled return including net dividends. Latest available market price: USD 438, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 438, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Intuitive Surgical forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Intuitive Surgical differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Intuitive Surgical is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Intuitive Surgical: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Intuitive Surgical at the latest market close (20 Oct 2026): $15,137 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
The base-case investment thesis balances secular surgical robotics adoption against structural multiple compression in a restrictive interest-rate regime. Intuitive Surgical's economic engine is anchored by an installed base exceeding 11,700 systems, generating over 80% recurring revenue through proprietary instruments, accessories, and service contracts. This razor-and-blade model decouples cash generation from lumpy hospital capital expenditure cycles. However, valuation sensitivity remains acute. At 45x trailing earnings, the equity functions as a long-duration asset vulnerable to discount-rate pressure and hospital capital rationing. Furthermore, self-inflicted price concessions via the 2027 Extended Use Program, alongside the arrival of cleared competitors, will decouple revenue growth from procedure volume.
Key insights
- Operating lease migration preserves installed-base placement velocity but lengthens cash payback periods and dilutes upfront revenue recognition across hospital networks.
- Extended-use instrument programs pre-emptively defend market share against emerging modular competitors but cap medium-term consolidated gross margin expansion below 68%.
- Free cash flow conversion exceeding 100% of net income funds continuous share repurchases, transforming operational compounding into per-share equity accretion.
Intuitive Surgical: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 438, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 393. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $399 | +1.54% | -8.90% | -8.90% | Year-end procedure volume resilience and initial da Vinci 5 commercial shipments counter restrictive monetary policy headwinds, allowing high-margin instrument turnover to support modest valuation stabilization. | $378 | $413 | $750 | |
| $407 | +1.92% | -7.08% | -7.08% | Fiscal 2027 guidance introduces conservative revenue-per-procedure assumptions from the extended-use instrument rollout and hospital capex freezes, prompting estimate recalibration and mild multiple compression. | $389 | $430 | $736 | |
| $421 | +3.48% | -3.88% | -3.88% | First-quarter procedure data confirms that underlying surgical volume growth remains durable above fourteen percent, while European regulatory momentum cushions domestic capital equipment procurement delays. | $393 | $455 | $743 | |
| $432 | +2.46% | -1.37% | -1.37% | Summer surgical seasonality moderates procedural turnover, but progressive adoption of force-feedback instrumentation and steady share repurchases maintain predictable per-share cash-flow compounding. | $385 | $469 | $755 | |
| $450 | +4.19% | +2.74% | +2.74% | Hospital fiscal year-end budget flushes drive a seasonal inflection in multiport replacements, lifting fourth-quarter console shipments and validating operating margin resilience above thirty percent. | $393 | $492 | $776 | |
| $458 | +1.82% | +4.57% | +4.57% | Rival commercial launches introduce competitive tender friction and pricing scrutiny, yet surgeon switching inertia and established clinical workflows prevent meaningful customer defection. | $397 | $512 | $787 | |
| $469 | +2.55% | +7.08% | +7.08% | Manufacturing scale on fifth-generation components reduces unit costs, absorbing instrument pricing concessions and driving healthy operating cash-flow conversion across expanded clinical indications. | $405 | $543 | $803 | |
| $483 | +2.91% | +10.27% | +10.27% | Recurring consumable replenishment across academic and community hospitals buffers seasonal procedure moderation, preserving solid free cash flow generation despite persistent high borrowing benchmarks. | $409 | $559 | $812 | |
| $502 | +3.87% | +14.61% | +14.61% | Year-end fleet upgrades accelerate as hospital networks standardize on advanced computational consoles, propelling annual operating cash flow and funding continued programmatic equity retirements. | $417 | $587 | $839 | |
| $515 | +2.69% | +17.58% | +17.58% | First-quarter procedural volumes maintain steady low-teens expansion, led by general surgery and thoracic indications, while leasing collections provide highly visible recurring cash streams. | $421 | $611 | $851 | |
| $531 | +3.04% | +21.23% | +21.23% | Early commercialization of digital surgical analytics and simulation subscriptions begins adding high-margin recurring software revenue, supporting steady incremental operating margin expansion. | $430 | $641 | $872 | |
| $545 | +2.56% | +24.43% | +24.43% | International procedure expansion across Europe and developed Asia compensates for domestic market maturation, maintaining overall revenue momentum despite competitive pressure in secondary markets. | $434 | $660 | $886 | |
| $564 | +3.56% | +28.77% | +28.77% | Robust fourth-quarter capital installations and record consumable shipments drive strong annual cash conversion, cementing the platform's role as an indispensable surgical utility. | $443 | $693 | $910 | |
| $575 | +1.96% | +31.28% | +31.28% | Demographic aging continues to expand non-discretionary oncology and pelvic floor caseloads, providing a predictable procedural floor that shields earnings from broader late-cycle macroeconomic deceleration. | $447 | $721 | $916 | |
| $587 | +2.02% | +34.02% | +34.02% | Expanded regulatory clearances for outpatient ambulatory surgery center applications broaden the accessible procedure pool, sustaining healthy instrument pull-through per installed console. | $456 | $757 | $937 | |
| $601 | +2.52% | +37.21% | +37.21% | Installed base scale exceeding fourteen thousand systems generates an unshakeable consumable toll, neutralizing seasonal elective procedure dips and preserving fortress balance sheet liquidity. | $461 | $780 | $947 | |
| $620 | +3.03% | +41.55% | +41.55% | Solid fiscal year-end console placements and expanding software integration generate superior cash conversion, enabling management to execute steady accretive share repurchases. | $470 | $811 | $970 | |
| $632 | +1.92% | +44.29% | +44.29% | Normalized low-teens procedural growth establishes a mature compounding cadence, where earnings expansion drives equity appreciation while terminal valuation multiples settle near historical medtech averages. | $470 | $835 | $980 | |
| $649 | +2.71% | +48.17% | +48.17% | Advanced endoscopic platforms and single-port applications deepen hospital workflow entrenchment, generating steady high-margin consumable turnover across diverse surgical specialties. | $479 | $877 | $1,000 | |
| $663 | +2.21% | +51.37% | +51.37% | The forecast period concludes with undisputed robotic ecosystem leadership, where massive procedural cash generation and pristine balance-sheet strength cement durable through-cycle shareholder returns. | $484 | $912 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Intuitive Surgical Stock Analysis & Scenarios Deep Dive
Intuitive Surgical: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market consensus views Intuitive Surgical as an elite medtech compounder whose da Vinci 5 rollout ensures uninterrupted mid-teens procedural compounding. Investors treat the razor-and-blade consumable model as largely impervious to broader economic headwinds. However, media commentary and sell-side price target reductions reflect growing anxiety that elevated sovereign bond yields, post-pandemic procedure normalization, and arriving soft-tissue competition from multinational healthcare conglomerates will permanently cap valuation multiples.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd modestly underestimates Intuitive's valuation durability, but overestimates the near-term velocity of outright hardware capital sales. The market fixates on quarterly console delivery optics, overlooking that recurring instruments and services generate over 80% of turnover. However, consensus models also ignore the 2027 Extended Use Program, which voluntarily surrenders instrument pricing per procedure to lock out competitors. This creates a nuanced alpha gap: operational compounding is more resilient than feared, but gross margins face a structural ceiling.
Repricing Catalyst
What could make the market recognize and close that gap? Upcoming financial reporting through fiscal 2027 will resolve the gap between headline capital equipment concerns and procedural cash durability. The critical trigger will be reported gross margin stability near 68% and sustained mid-teens recurring consumable revenue expansion as da Vinci 5 utilization deepens. Confirmation that instrument pull-through outpaces hardware placement lumpiness will compel institutional asset allocators to reprice the shares based on resilient through-cycle cash flows.
Intuitive Surgical: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Stabilization
Sentiment exhibits fear driven by multiple compression and healthcare capex tightening, yet volatility expectations remain moderate. The primary disagreement centers on whether the stock is stabilizing into a mature compounder or risking further multiple de-rating as competitors enter.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing monetary regime of elevated policy rates and restrictive sovereign yields presents a clear headwind for hospital debt financing and equity duration multiples. However, surgical procedure demand exhibits near-zero elasticity to macroeconomic cycles. Intuitive's zero-debt fortress balance sheet, substantial net cash reserves, and self-funded capital deployment insulate operations, transforming external credit constraints into a relative competitive moat against levered medtech rivals.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary debate across reports concerns terminal valuation multiples and the durability of pricing power. Bullish analyses assume that procedural compounding and surgeon residency lock-in will preserve a premium multiple above 40x earnings, arguing that competitor platforms will remain irrelevant. Conversely, cautious perspectives emphasize that 5% bond yields fundamentally re-rate growth equities, while the commercial arrival of Medtronic's Hugo and J&J's Ottava arms hospital procurement committees with bargaining leverage. Furthermore, reports disagree on whether the 2027 Extended Use Program represents a margin-diluting price concession or an unassailable defensive moat that accelerates customer volume.
Intuitive Surgical: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Recurring Consumables Tollbooth Compounding | Competitive Positioning | +28% | +35% | Proprietary instruments, specialized accessories, and multi-year service contracts generate over 80% of total revenue. As worldwide surgical procedures expand at 14% to 16% annually across general surgery, thoracic, and colorectal indications, recurring consumable turnover compounds automatically. This procedure-linked tollbooth shields cash generation from hospital capital expenditure freezes, ensuring predictable double-digit operational cash flows across macroeconomic cycles. |
| Fifth-Generation Platform Upgrade Supercycle | Innovation And Product | +24% | +26% | The commercial deployment of da Vinci 5 drives a multi-year hardware replacement cycle across an installed base exceeding 11,700 systems. Featuring force-feedback sensing, tenfold computational processing capability, and 11% higher procedural throughput, the console compels health networks to upgrade aging fleets. This platform refresh commands premium average selling prices and locks in multi-year service contracts. |
| Global Demographic Minimally Invasive Migration | Sector And Industry | +18% | +20% | Aging populations across North America, Europe, and developed Asia structurally drive incidence curves in oncological, urological, and soft-tissue pathologies. Concurrently, hospital administrators prioritize robotic minimally invasive interventions to shorten inpatient hospital stays and lower surgical complication rates. This clinical necessity expands procedure volumes and drives geographic penetration across under-indexed international healthcare delivery systems. |
| Fortress Balance Sheet Self-Funded Buybacks | Capital Allocation | +14% | +15% | Intuitive generates trailing free cash flow exceeding $3.2 billion with zero gross debt and over $8.6 billion in liquid reserves. Having completed major manufacturing facility expansions, capital expenditure intensity has normalized near 5% of revenue. Management redeploys surplus cash into programmatic share repurchases, systematically retiring equity float and accreting per-share earnings without relying on debt markets. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Restrictive Cost of Capital Compression | Macroeconomic And Macrofinancial | -17% | -4.0% | Sovereign bond yields near 5.0% and central bank policy rates around 4.0% impose persistent discount-rate gravity on long-duration healthcare growth equities. Intuitive's trailing price-to-earnings multiple of 45x faces structural resistance against returning to historical peak multiples. This macroeconomic constraint forces shareholder returns to track underlying operational earnings compounding rather than multiple re-expansion. |
| Hospital Capital Freezes and Leasing Shift | Macroeconomic And Macrofinancial | -13% | -11% | Healthcare systems facing labor cost inflation and tight operating margins are increasingly deferring outright multimillion-dollar console purchases. Instead, hospitals demand operating leases and usage-based financing. While leasing preserves long-term placement volume, it defers upfront hardware revenue recognition, increases Intuitive's balance-sheet asset commitments, and modestly dampens near-term return on invested capital. |
| Cleared Multiport Competitor Tender Encroachment | Competitive Positioning | -11% | -10% | Regulatory clearances for Medtronic's Hugo and Johnson & Johnson's Ottava platforms formally end Intuitive's absolute domestic monopoly in soft-tissue robotics. While clinical switching barriers and surgeon training remain formidable moats, hospital procurement committees exploit competing platforms to demand instrument bundle discounts and favorable trade-in terms, exerting downward pressure on hardware pricing. |
| Extended-Use Pricing and Procurement Concessions | Regulatory | -9.0% | -10% | The scheduled rollout of extended-use instruments in 2027 deliberately lowers customer cost-per-procedure in high-volume benign surgeries to deny rivals a market opening. However, this self-inflicted concession decouples instrument revenue growth from underlying procedure expansion. Combined with international volume-based procurement pressures, this dynamic establishes an observable near-term ceiling on gross margin expansion. |
Intuitive Surgical: What Could Break or Accelerate the Thesis
Event Risk Score: Low 34/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Federal Robotic Procedural Reimbursement Carve-Out | 22% | -28% | Mounting healthcare entitlement deficits could prompt CMS to enact restrictive bundled payments or site-neutral caps that eliminate premium reimbursement for robotic-assisted laparoscopic surgery by 2028. Lacking financial incentives in routine hernia or gallbladder repairs, hospitals would curtail robotic consumable utilization, reducing procedure growth to single digits and compressing gross margins. |
| Catastrophic Systemic Sensor Recall Event | 14% | -34% | A critical defect in da Vinci 5's force-feedback sensor architecture or an algorithmic firmware flaw leading to intraoperative vascular complications could trigger a mandatory FDA Class I recall. Regulators would halt console shipments and suspend surgical procedures pending retrofits, inflicting massive remediation costs, litigation liabilities, and severe reputational damage. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Autonomous Surgical Guidance Regulatory Breakthrough | 28% | +32% | Regulators could grant breakthrough clearance by 2028 for real-time intraoperative AI surgical guidance and automated suturing sub-tasks on da Vinci 5. This would transform the console from a tele-manipulator into an active clinical assistant, unlocking recurring enterprise software subscriptions of over $150,000 annually per system and expanding gross margins beyond 72%. |
| Universal Outpatient Ambulatory Surgical Penetration | 32% | +25% | A coordinated overhaul by CMS and commercial payers establishing enhanced, site-neutral procedural reimbursement parity by 2027 would accelerate robotic adoption in ambulatory surgery centers. Intuitive's compact single-port and da Vinci 5 variants would rapidly penetrate outpatient facilities, doubling addressable domestic surgical volume and expanding consumable sales beyond 22% annually. |
Company Financial AnalysisIntuitive Surgical: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Intuitive Surgical financials here.
Earnings and financials
Intuitive's financial performance demonstrates an exceptional compounding engine driven by non-discretionary patient procedures. Trailing twelve-month revenue reached $11.03 billion by mid-2026, supported by robust 18.5% year-over-year growth in the second quarter. Net income advanced to $3.14 billion, propelled by double-digit procedure growth and expanding demand for the da Vinci 5 system. Crucially, recurring sales of single-use instruments, accessories, and maintenance contracts now represent over 80% of total turnover, insulating top-line performance from cyclical healthcare slowdowns. The real strength of this business lies in its remarkable cash generation. Trailing free cash flow reached $3.22 billion, converting net income into cash at a rate exceeding 100%. This highlights an essential procedural utility whose cash generation remains completely self-funding.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 10.1B | USD 2.9B | USD 2.5B |
| 2024 | USD 8.4B | USD 2.3B | USD 1.3B |
| 2023 | USD 7.1B | USD 1.8B | USD 749.6M |
| 2022 | USD 6.2B | USD 1.3B | USD 958.4M |
| 2021 | USD 5.7B | USD 1.7B | USD 1.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 71.5x | TTM | Native | USD / USD |
| 2024 | 81.8x | TTM | Native | USD / USD |
| 2023 | 67.2x | TTM | Native | USD / USD |
| 2022 | 71.6x | Annual | Native | USD / USD |
| 2021 | 77.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Operating profitability exhibits structural resilience anchored by high-margin consumable instrument sales. Gross margin held stable at 66.0% in fiscal 2025, while operating margin expanded to 29.3%, reaching 31.3% on a trailing twelve-month basis by mid-2026. This operational leverage shows that steady procedural volume growth and administrative cost control easily absorbed early manufacturing startup expenses for the da Vinci 5 console. The underlying story is driven by a highly favorable product mix. Recurring instruments and services generate gross margins near 70%, offsetting the introductory overhead of building advanced robotic consoles. As manufacturing efficiencies for new sensors mature, fixed factory costs will spread across higher unit volumes, structurally protecting operating margins despite competitive market pressures.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 2.9B | 29.3% | 28.4% |
| 2024 | USD 2.3B | 28.1% | 27.8% |
| 2023 | USD 1.8B | 24.8% | 25.2% |
| 2022 | USD 1.6B | 25.3% | 21.3% |
| 2021 | USD 1.8B | 31.9% | 29.9% |
Balance sheet and leverage
Intuitive maintains a classic fortress balance sheet engineered for complete strategic independence. The company operates with zero long-term funded debt, carrying a debt-to-equity ratio of just 0.02 that reflects only standard operating leases. With total stockholders' equity of $17.82 billion, a current ratio of 4.87, and over $8.6 billion in cash and liquid investments, the business faces no debt refinancing risks in a high-interest-rate world. This liquidity buffer provides vital strategic flexibility. While financially strained hospital customers navigate higher borrowing benchmarks, Intuitive can comfortably offer flexible equipment leasing structures directly from its own reserves. Furthermore, management can opportunistically deploy billions into share repurchases during broader market downturns without compromising its intensive research programs.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 302.8M | USD 5.9B | USD 3.1B net cash | USD -5.6B | 4.87x |
| 2024 | USD 146M | USD 4B | USD 1.9B net cash | USD -3.9B | 4.07x |
| 2023 | USD 89.8M | USD 5.2B | USD 2.8B net cash | USD -5.1B | 4.76x |
| 2022 | USD 93.8M | USD 4.1B | USD 1.6B net cash | USD -4B | 4.40x |
| 2021 | USD 87M | USD 4.2B | USD 1.2B net cash | USD -4.1B | 5.08x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management has transitioned capital spending from heavy infrastructure construction into operational cash harvesting. After committing between 13% and 15% of revenue to facility buildouts during 2023 and 2024 to support fifth-generation manufacturing, capital expenditures moderated to 5.4% of revenue in fiscal 2025. This planned reduction released substantial cash flow without constraining production capacity, leaving the business with ample manufacturing headroom to support global platform rollouts. Meanwhile, internal investment remains firmly focused on technological leadership, with research and development spending climbing to $1.31 billion in 2025. By funding proprietary force-sensing instruments and computational software out of internally generated cash flow, Intuitive expands its competitive lead while keeping its operations highly capital-efficient.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 539.8M | USD 1.3B |
| 2024 | USD 1.1B | USD 1.1B |
| 2023 | USD 1.1B | USD 998.8M |
| 2022 | USD 532.4M | USD 879M |
| 2021 | USD 353.5M | USD 671M |
Behind the synthesisIntuitive Surgical: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The common pattern supported by empirical evidence is that surgical procedure volume remains largely non-cyclical, driving high-margin recurring instrument and accessory revenue that shields corporate cash generation from broader macroeconomic stagnation. However, reports heavily diverge on terminal multiple behavior and capital placement velocity. Correlated bullish assumptions treat hospital system purchases as frictionless and ignore the margin-diluting reality of customer leasing models. The strongest contrarian insight confirms that Intuitive faces self-inflicted and competitive pricing concessions starting in 2027 through extended-use instrument programs and rival platform clearances, capping gross margin expansion. Unresolved uncertainties include the durability of outpatient surgical migration and geopolitical procurement caps in Asia. Consequently, relative weights prioritize rigorous, source-grounded analyses that disaggregate non-recurring tariff windfalls, penalize aggressive multiple expansion under restrictive monetary policy, and realistically model operating-lease financing burdens on capital efficiency.
All 14 opinions
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 14.8%
Exceptional evidence quality with verified primary source documentation. Explicitly models the margin trade-offs of the 2027 Extended Use Program and regulatory coverage transitions, presenting the most rigorous causal analysis of competitive entry and procedural economics.
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 14.8%
Rigorous, primary-source-backed framework incorporating regulatory filings and FOMC statements. Accurately disaggregates tariff refund windfalls from organic gross margins, properly treating hospital leasing as balance-sheet capital deployment rather than frictionless recurring revenue.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.3%
Thoughtful assessment of multiple deflation under restrictive monetary policy, acknowledging surgical data telemetry moats alongside the reality of robotic hardware maturity. Accurately identifies that procedural compounding must outrun terminal multiple compression.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.4%
Provides sound balance between hospital capital equipment budget friction and non-discretionary procedural volume expansion. Grounded in trailing financials, recognizing that recurring consumables insulate gross cash flow, though slightly underestimates margin compression from extended-use programs.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.4%
Thorough forensic examination of cash conversion, working capital headroom, and capital expenditure tapering. Provides balanced path modeling, though downplays potential pricing erosion from emerging modular competitors in price-sensitive international tenders.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.4%
Provides a crucial cautionary perspective on leasing mix shifts and hospital credit distress. Identifies how operating leases delay upfront revenue recognition, though slightly overstates the speed of competitive tender displacement.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Strong macroeconomic framing of interest rate transmission to municipal hospital capital budgets. However, it relies on formulaic rhetorical queries and slightly overstates terminal earnings multiples relative to peer medtech historical de-rating patterns.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.5%
Sound focus on owner earnings, high cash conversion, and balance sheet fortification. Offers realistic compounding expectations, though remains somewhat sanguine regarding foreign volume-based procurement hurdles in Asian healthcare markets.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.6%
Compelling biological demand argument highlighting inelastic procedural need. However, relies heavily on complex theoretical jargon and adopts a volatile quarterly return path that exceeds historical procedural revenue stability.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.6%
Prudent examination of razor-and-blade economics and da Vinci 5 throughput advantages. Accurately models share repurchase accretion, but projects a relatively benign path that overlooks near-term extended-use pricing concessions.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.6%
Offers valuable institutional analysis regarding surgeon training capture and residency lock-in. Nevertheless, projects aggressive terminal multiple expansion to fifty-two times earnings that contradicts prevailing macroeconomic tightening and capital rationing pressures.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.6%
Synthesizes data telemetry and hospital negentropy advantages well, but projects an elevated terminal multiple of thirty-six times earnings alongside fifty-percent revenue expansion that underestimates public single-payer healthcare budgetary caps.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.7%
Presents an aggressive multiple expansion scenario that underestimates duration headwinds in a restrictive interest-rate environment. While correctly assessing recurring revenue density, assuming multiple expansion past forty times earnings under five-percent bond yields lacks macroeconomic consistency.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 2.8%
Heavily overweighted toward an imperial monopoly thesis that dismisses rival regulatory approvals too readily. Projects overly optimistic price returns without sufficiently accounting for hospital procurement committee leverage and long-duration equity multiple compression.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Intuitive Surgical forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web33 available sources from this batch (67 recorded). The first 15 are shown below; expand to read the rest.
- Federal Reserve Board - Federal Reserve issues FOMC statement federalreserve.gov
- https://www.sec.gov/Archives/edgar/data/1035267/000103526726000047/q226ex-991earningsrelease.htm?utm_source=openai sec.gov
- INTUITIVE SURGICAL INC - Form 8-K - FY2026 sec.gov
- isrg-20251231 sec.gov
- isrg-20260630 sec.gov
- www.sec.gov sec.gov
- ISRG Stock Sinks as Analysts Cut Price Targets on Intuitive Surgical barchart.com
- 2027 trends to watch: Coverage losses will challenge healthcare growth strategies definitivehc.com
- Intuitive Announces Second Quarter Earnings finance.yahoo.com
- Intuitive Surgical, Inc. Q2 2026 Earnings Call Summary finance.yahoo.com
- Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too. | The Motley Fool fool.com
- Earnings call transcript: Intuitive Surgical beats Q2 2026 estimates, shares fall By Investing.com investing.com
- Da Vinci 5 Cleared for Cardiac Procedures | Intuitive Surgical isrg.intuitive.com
- Intuitive Announces First Quarter Earnings | Intuitive Surgical isrg.intuitive.com
- Intuitive Announces Fourth Quarter Earnings | Intuitive Surgical isrg.intuitive.com
Show 18 more sources
- Intuitive Announces Second Quarter Earnings | Intuitive Surgical isrg.intuitive.com
- Intuitive Shares Vision for an AI-Enabled Future of Healthcare | Intuitive Surgical isrg.intuitive.com
- Microsoft PowerPoint - Investor Presentation Q226 Final isrg.intuitive.com
- Stock Information | Intuitive Surgical isrg.intuitive.com
- Intuitive Surgical (ISRG) Stock Forecast and Price Target 2026 marketbeat.com
- Johnson & Johnson wins FDA nod for Ottava surgical robot massdevice.com
- Intuitive ties Q2 procedure softness to ACA subsidy expirations | MedTech Dive medtechdive.com
- J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive | MedTech Dive medtechdive.com
- Medtronic’s Hugo surgical robot earns FDA clearance | MedTech Dive medtechdive.com
- Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures - Dec 3, 2025 news.medtronic.com
- Why Intuitive Surgical (ISRG) Stock Is Down Today | Quiver Quantitative quiverquant.com
- On Medicaid work requirements, the end of ACA enhanced subsidies and ACAP’s 25th anniversary – RamaOnHealthcare ramaonhealthcare.com
- How ACA Subsidy Expiration Really Impacts Health Care Markets in 2026 sageadvisory.com
- Intuitive maintains 13.5%-15.5% 2026 da Vinci procedure growth outlook while outlining 68%-69% non-GAAP gross margin range (NASDAQ:ISRG) | Seeking Alpha seekingalpha.com
- J&J Ottava FDA Clearance Breaks da Vinci’s Two-Decade Soft-Tissue Monopoly techtimes.com
- Intuitive Surgical Raises 2026 Procedure Guidance After a 40% EBIT Jump: Analysts Price ISRG Above $700 | TIKR.com tikr.com
- Intuitive Surgical Stock Has Fallen 39% From Its High. Could This Be the Bottom? | TIKR.com tikr.com
- Intuitive Surgical: Down 34% From Its ATH, Procedures Growing 17%, Guidance Raised Anyway tuialailima.com
34 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.